Heart Failure and Preserved Left Ventricular Function: Long Term Clinical Outcome

Israel Gotsman*, Donna Zwas, Chaim Lotan, Andre Keren
Heart Institute, Hadassah University Hospital, Jerusalem, Israel

Abstract

**Background:** Patients with heart failure (HF) have a poor prognosis. The proportion of patients with HF and preserved left ventricular function (LVF) is increasing. Long term prognosis of HF with preserved LVF may not be so benign.

**Objectives:** To evaluate the long term clinical outcome of patients with HF and preserved LVF and predictors of outcome.

**Methods:** We prospectively evaluated 309 patients hospitalized with a definite clinical diagnosis of HF. Patients were followed for a mean of 6.5 years for clinical outcome.

**Results:** More than a third (36%) of the patients had preserved systolic LVF based on echocardiography. The long term survival rate in this group was poor and not significantly different from patients with reduced LVF (28% vs 23% respectively, \( P = 0.2 \)). The adjusted survival rate by Cox regression analysis was also not significantly different (hazard ratio 1.16, 95% confidence interval 0.87–1.55, \( P = 0.31 \)). The event free survival from death or heart failure re-hospitalization was also low in both groups and not significantly different between patients with preserved vs. reduced LVF (12% vs. 10% respectively, \( P = 0.2 \)). Predictors of mortality in patients with preserved LVF were age, functional capacity and serum urea levels.

**Conclusions:** The long term clinical outcome of patients with heart failure and preserved LVF is poor and not significantly different from patients with reduced LVF.

Background

Heart failure (HF) is a major epidemic and a significant public health problem [1]. The clinical syndrome of heart failure with preserved left ventricular function (LVF) also defined as HF with a normal ejection fraction, is a common condition in patients with HF and has emerged as a serious clinical problem. A study showed that over the past two decades there has been a significant increase in the number of patients admitted to hospital with heart failure and preserved LVF [2]. The outcome in these patients may be better than in patients with reduced LVF. However, recent studies suggest that the prognosis in these patients is not so benign [2,3]. We have previously reported the short term outcome of patients with preserved LVF, and shown that they have a poor prognosis [4]. The aim of the present study was to evaluate the long term clinical outcome of patients with heart failure and preserved LVF and compare the outcome to reduced LVF. We also evaluated predictors of outcome in these patients.

Methods

**Patients**

We prospectively enrolled consecutive patients with HF admitted to an Internal Medicine department with a definite diagnosis of HF. HF was not necessarily the primary cause for hospital admission. Diagnosis of HF during hospitalization was made by the treating physician, and was corroborated either by clinical symptoms and signs consistent with HF, reduced left ventricular function (LVF) by echocardiogram or both. Clinical diagnosis of HF was based on typical symptoms and signs consistent with heart failure: orthopnea, paroxysmal nocturnal dyspnea, elevated jugular venous pressure, ankle edema, hepatomegaly or an enlarged cardiac silhouette on chest X-ray. Echocardiograms included were only those that were performed up to 6 months before enrollment. Classification of LVF by echocardiogram was qualitative using a visual assessment of normal, preserved, mild, moderate or severely reduced LVF. We recruited 362 consecutive patients hospitalized with a definite diagnosis of heart failure during a two year period from January 2001 to December 2002. Echocardiographic data was available in 309 (85%) of the patients. There were no significant differences in the clinical parameters between patients with or without echocardiography. Patients with echocardiography were the cohort of this study. The patients were divided into two groups according to the systolic function by echocardiogram: patients with normal or preserved LVF and patients with mild to severely reduced LVF. The study protocol was approved by the Hadassah-Hebrew University Medical Center Institutional Committee for Human Studies. A waiver was obtained from the institutional committee.
# Table 1. Demographics and clinical characteristics of the patients with CHF.

| Demographics and Clinical characteristics | Preserved LVF (N = 111) | Reduced LVF (N = 198) | All (N = 309) | P value |
|------------------------------------------|-------------------------|-----------------------|--------------|---------|
| Age (years)                              | 75±12                   | 72±12                 | 73±12        | 0.07    |
| Male                                     | 39 (35%)                | 126 (64%)             | 165 (53%)    | <0.001  |
| Admission due to HF                      | 66 (59%)                | 120 (61%)             | 186 (60%)    | 0.8     |
| Hospital mean duration (days)            | 10±6                    | 9±7                   | 9±7          | 0.3     |
| NYHA FC Class III-IV                     | 79 (71%)                | 143 (72%)             | 222 (72%)    | 0.8     |
| Admission Systolic BP (mmHg)             | 142±32                  | 132±28                | 136±29       | <0.01   |
| Admission Diastolic BP (mmHg)            | 75±15                   | 72±13                 | 73±14        | 0.06    |
| Pulse Pressure (mmHg)                    | 67±23                   | 61±22                 | 63±23        | 0.02    |
| Admission Pulse (bpm)                    | 81±17                   | 82±21                 | 81±19        | 0.8     |
| Peripheral Edema                         | 63 (57%)                | 107 (54%)             | 170 (55%)    | 0.6     |
| Pulmonary Congestion - CXR               | 47 (42%)                | 93 (47%)              | 140 (45%)    | 0.4     |
| Concurrent Illnesses                     |                         |                       |              |         |
| Ischemic Heart Disease                   | 61 (55%)                | 148 (75%)             | 209 (68%)    | <0.001  |
| S/P Myocardial Infarction                | 20 (18%)                | 66 (33%)              | 86 (28%)     | <0.01   |
| S/P Coronary bypass surgery              | 8 (7%)                  | 44 (22%)              | 52 (17%)     | <0.001  |
| Hypertension                             | 68 (61%)                | 104 (53%)             | 172 (56%)    | 0.1     |
| Diabetes Mellitus                        | 42 (38%)                | 84 (42%)              | 126 (41%)    | 0.4     |
| Hyperlipidemia                           | 25 (23%)                | 61 (31%)              | 86 (28%)     | 0.1     |
| Valve Disease                            | 30 (27%)                | 42 (21%)              | 72 (23%)     | 0.2     |
| Atrial Fibrillation                      | 40 (36%)                | 62 (31%)              | 102 (33%)    | 0.4     |
| Peripheral Vascular Disease              | 6 (5%)                  | 27 (14%)              | 33 (11%)     | 0.02    |
| S/P TIA or CVA                           | 10 (9%)                 | 28 (14%)              | 38 (12%)     | 0.2     |
| Chronic Obstructive Lung                 | 36 (32%)                | 49 (25%)              | 85 (28%)     | 0.1     |
| Laboratory Data on Discharge             |                         |                       |              |         |
| Hemoglobin (g/dl)                        | 11.3±2.1                | 11.4±1.8              | 11.3±1.9     | 0.6     |
| Serum Creatinine (umol/L)                | 129 (95–177)            | 120 (90–162)          | 134 (96–181) | 0.2     |
| Serum Urea (mmol/L)                      | 12.8 (8.9–19.4)         | 12.1 (8.4–18.2)       | 13.7 (9.3–19.6) | 0.2     |
| Serum Na+ (mEq/L)                        | 139 (135–141)           | 139 (135–142)         | 140 (135–141) | 0.8     |
| Echocardiography Data                    |                         |                       |              |         |
| LA size (cm)                             | 5.9±1.0                 | 5.9±0.8               | 5.9±0.9      | 0.7     |
| LV EDD (cm)                              | 5.0±0.6                 | 5.9±0.9               | 5.6±0.9      | <0.001  |
| LV ESD (cm)                              | 3.2±0.5                 | 4.8±1.0               | 4.2±1.1      | <0.001  |
| Intraventricular Septum (cm)             | 1.15±0.21               | 1.01±0.30             | 1.06±0.27    | <0.01   |
| Severe Mitral Regurgitation              | 16 (15%)                | 27 (15%)              | 43 (15%)     | 0.7     |
| Reduced RVF                              | 27 (26%)                | 83 (43%)              | 110 (37%)    | <0.01   |
| Tricuspid inflow PG (mmHg)               | 42.5±15.4               | 38.0±13.2             | 39.8±14.3    | 0.03    |
| Pharmacological Treatment on Discharge   |                         |                       |              |         |
| ACE-inhibitor/ARB                        | 77 (69%)                | 142 (72%)             | 219 (71%)    | 0.6     |
| Beta blockers                            | 30 (27%)                | 112 (57%)             | 142 (46%)    | <0.001  |
| Spironolactone                           | 32 (29%)                | 55 (28%)              | 87 (28%)     | 0.8     |
| Furosemide                               | 84 (76%)                | 142 (72%)             | 225 (73%)    | 0.9     |
| Digoxin                                  | 18 (16%)                | 52 (26%)              | 70 (23%)     | 0.05    |
| Nitrates                                 | 41 (37%)                | 93 (47%)              | 133 (43%)    | 0.1     |
| Calcium channel blockers                 | 36 (32%)                | 34 (17%)              | 70 (23%)     | <0.01   |
| Statins                                  | 25 (23%)                | 61 (31%)              | 86 (28%)     | 0.1     |
| Anticoagulants                           | 29 (26%)                | 41 (21%)              | 70 (23%)     | 0.3     |
| Aspirin                                  | 47 (42%)                | 116 (59%)             | 163 (53%)    | 0.02    |
for written informed consent as the study was exclusively observational.

Hospital Evaluation

Sociodemographic status including place of residence, ethnic background, education, background (concurrent) diseases as documented by the medical records, the causes of admission and drug prescription on discharge were recorded systemically from the medical records during hospitalization. Echocardiography data including measurements of dimensions and intraventricular septal wall thickness were performed according to standard recommendations of the American Society of Echocardiography and were evaluated and verified by qualified personnel. Left ventricular (LV) and right ventricular (RV) systolic function were assessed qualitatively: normal, mild, moderate and severely reduced function. Comprehensive diastolic indices were not available for analysis.

Follow-up Evaluation

Patients were clinically followed by telephone up to September 2008. Clinical outcome including the number of re-hospitalizations and death were evaluated. Hospitalizations due to HF exacerbation were also recorded. Hospitalizations due to HF exacerbation was based on a primary diagnosis of this condition on the admission hospital records. Mortality was based on data from the National Census Bureau.

Statistical Analyses

SPSS version 17.0 for Windows (SPSS Inc., Chicago, Illinois, USA) was used in all analyses. The student’s t test or Mann-Whitney U test for continuous variables and the Chi-square test for categorical variables was used to examine the bivariate comparisons for each of the demographic or clinical parameters between patients with preserved versus reduced LVF. Clinical predictors were transformed where appropriate. Log_{10} was used for logarithmic transformations. Kaplan-Meier curves, with the log-rank test, were used to compare survival among the two groups. Multivariate Cox regression analysis was used to evaluate independent variables that determined survival. Parameters included in the multivariate Cox regression analysis incorporated all significant clinical and laboratory parameters on univariate analysis as well as drug treatment. Parameters that were included in the multivariate analysis were age, gender, ischemic heart disease, hypertension, diabetes, atrial fibrillation, admission due to HF, serum urea, sodium, hemoglobin, functional capacity and LVF. Proportionality assumptions of the Cox regression models were evaluated by log-log survival curves and with the use of Schoenfeld residuals. Possible interactions were assessed. A p value of <0.05 was considered statistically significant.

Results

Clinical Parameters

The study cohort consisted of 309 consecutive patients hospitalized with a definite diagnosis of HF. Follow-up was complete in all patients. Mean follow-up was 6.5 years. 198 had reduced LVF and 111 (36%) had preserved LVF. The demographics, clinical parameters, echocardiographic data and pharmacological treatment on discharge of these patients are presented in Table 1. Patients with preserved LVF were older and were more likely to be females. These patients also had less ischemic heart disease. NYHA Functional class was not significantly different between the two groups. Admission systolic blood pressure and pulse pressure were higher in patients with preserved LVF. Patients with preserved LVF received less beta-blockers, aspirin and digoxin but received more calcium blockers.

Echocardiographic Data

Left ventricular end systolic and end diastolic diameters were smaller in patients with preserved LVF (Table 1). The mean intraventricular septum (IVS) was thicker in patients with preserved LVF and a higher proportion of the patients had abnormal IVS thickness (IVS>1.1 cm): 50% vs. 32%, P=0.02. Right ventricle function was normal in a larger percentage of patients with preserved LVF. The mean pulmonary pressure estimated by the tricuspid inflow pressure gradient was higher in these patients. However, any degree of pulmonary hypertension (>35 mmHg) was common in both groups (80% vs. 72% in preserved vs. reduced LVF respectively, P=0.1).

Clinical Outcome

The survival rate in patients with preserved LVF was poor and not significantly different from patients with reduced LVF (28% vs 23% respectively P=0.2, Figure 1A). The clinical event-free rate that included death or heart failure re-hospitalization was low in both groups and not significantly different between patients with preserved vs. reduced LVF (12% vs. 10% respectively, P=0.2, Figure 1B). Re-hospitalization event-free rate from any reason was also low and very similar in both groups (13% versus 10% respectively, P=0.9, Figure 1C).

Predictors of Outcome

Variables included in the Cox regression analysis were age, gender, IHD, hypertension, diabetes, atrial fibrillation, admission due to HF, serum sodium, urca, hemoglobin, NYHA functional class and LV function. Predictors of increased mortality by multivariate Cox regression analysis in the whole group were age, male gender, functional capacity, hemoglobin level, discharge serum sodium and urea (Table 2). Preserved LVF was not a significant predictor of survival. Exclusion of patients with significant valve disease did not significantly change the results.

| Demographics and Clinical characteristics | Preserved LVF (N=111) | Reduced LVF (N=198) | All (N=309) | P value |
|-----------------------------------------|----------------------|---------------------|------------|---------|
| Anti-arrhythmic                          | 24 (22%)             | 41 (21%)            | 65 (21%)   | 0.8     |

Data is presented as mean = standard deviation or median (interquartile range) for continuous variables and counts (percentages) for categorical variables. P value by the student T test or Mann-Whitney U test for continuous variables and the Chi-Square Test for categorical variables.
Inclusion of specific drug therapies in the model did not alter the data. Analysis of predictors in each group separately revealed that significant predictors in patients with preserved LVF were age, functional capacity and serum urea levels (Table 2). Independent predictors of increased death or heart failure re-hospitalization in the whole group were age (hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.01–1.03, P<0.001), hemoglobin level (HR 0.90, 95% CI 0.94–0.96, P<0.01) and NYHA class III/IV (HR 1.90, 95% CI 1.42–2.54, P<0.001). Preserved LVF was not a significant predictor (HR 1.17, 95% CI 0.90–1.52, P=0.25).

Discussion

The syndrome of HF has become a major epidemic in the western world, leading to significant morbidity and mortality and it presents a significant global health burden. While systolic dysfunction is considered as the major cause of the syndrome, many of the patients have preserved systolic function. HF with preserved LVF is common and its incidence has increased in the last few decades [2]. The present study, based on a hospitalized cohort of patients, showed that 36% of the patients had preserved function. This is similar to most studies demonstrating that 30 to 50% of patients with heart failure have preserved systolic function (LVEF >50%) [2,5,6,7,8,9].

The clinical picture of these patients is different from patients with reduced LVF. In our study, the patients were older and were more likely to be females. These patients also had less ischemic heart disease. These characteristics are typical of patients suffering from this syndrome [10]. They also have more hypertension and atrial fibrillation [3,9] but have less ischemic heart disease [11,12]. Diastolic dysfunction is commonly found in most of these patients [13] and is probably a major contributory cause of the symptoms.

In the present study, we found that patients with preserved LVF had smaller heart sizes with increased left ventricular hypertrophy as evident by increased IVS thickness. This has been previously reported [7,14,15]. Increased wall thickness and LV mass with normal or reduced LV volume is usually present and LV mass/volume ratio was shown to be markedly increased in these patients [14]. Pulmonary pressures in our study were also higher in patients with preserved LVF compared to patients with reduced LVF. Even after exclusion of patients with significant mitral disease or pulmonary disease, mean pressures were increased in these patients. A recent study demonstrated that pulmonary hypertension is common in patients with preserved LVF and predicts mortality [16]. The increased LV wall thickness predisposes these patients to elevated LV end diastolic pressures causing the clinical syndrome of heart failure. It has been established that patients with heart failure and preserved LVF have significant abnormalities in active relaxation and passive stiffness causing decreased LV compliance [17,18] Decreased LV compliance is associated with a disproportionate elevation of the diastolic pressure, which causes a passive increase in left atrial and pulmonary venous pressures, which produces symptoms of pulmonary venous congestion and increases pulmonary pressures.

Prognosis in patients with preserved LVF was considered to be more benign than in patients with reduced LVF. Reduced EF, particularly below 45% [19] is considered a predictor of a poor outcome in patients with HF. A recent meta-analysis using individual patient data demonstrated that the risk of death did not increase notably until EF fell below 40% [20]. Despite this, the prognosis in patients with HF and preserved LVF is also dismal. Some studies suggest that the survival might be better in such patients; but, the differences are usually not large [2,9,11,21,22,23]. Most recent studies demonstrate that although...
the absolute survival in numbers tends to be slightly better in patients with preserved LVF, this difference is not statistically significant [3,5,6,7,8,12]. In the present study we found a very similar result: the survival was slightly better in these patients, however this was not significantly different even after adjustment for background diseases. In addition, significant clinical event rates including death and heart failure rehospitalization was similar with no difference between the groups. We also found that the rate of hospitalization due to any cause was very similar between both groups. The negligible difference in the long term outcome between the two groups was very similar to the short term (1 year) outcome rate in these patients [4]. These findings support the poor prognosis of patients with heart failure and preserved LVF and strengthen the need to find ways to improve prognosis in this common syndrome.

Patients with preserved LVF have a poor prognosis. The precise reasons for this have yet to be determined. This could be due to the syndrome of heart failure or due to comorbid conditions. Data regarding this is limited. A recent study showed that the cause of death was due to heart failure in 46% of these patients, a percentage that was not significantly different from patients with reduced function [24]. Although the clinical characteristics of patients with preserved LVF are quite distinct from patients with reduced LVF, the clinical syndromes are very similar. Furthermore, patients with heart failure and preserved LVF have pathophysiological abnormalities that are qualitatively very similar to patients with reduced LVF. These include hemodynamic changes that increase end diastolic pressures causing reduced exercise performance and activation of the neuroendocrine axis [14]. Reduced functional capacity and increased neurohormonal activation are strong predictors of outcome in patients with HF. It is possible that similar pathophysiological changes predispose patients in both subsets to a similar fate. In the present study, reduced functional capacity was a strong predictor of mortality in patients with preserved as well as reduced LVF.

Treatment modalities for patients with HF and preserved LVF that improve prognosis have yet to be discovered. Traditional therapies with definite benefit in patients with HF and reduced LVF have failed to improve prognosis in patients with preserved LVF. Recently, a small study demonstrated that the aldosterone receptor antagonist spironolactone reduced IVS thickening, inducing favorable cardiac remodeling in diastolic heart failure patients [25]. The beneficial effect of aldosterone receptor antagonism in preserved LVF is presently being tested in randomized clinical trials such as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study.

Limitations of this study: We delineated patients with preserved versus reduced LVF based on qualitative echocardiographical data and not on LV ejection fraction. However, qualitative data of normal or preserved LVF correlates well with an EF above 50% and patients with reduced function have an EF below 50%. Another limitation of this study is that we included patients based on clinical grounds and not on an objective test for HF. Furthermore, only patients hospitalized in internal medicine wards were recruited to this study. Therefore, the results can only be applied to such a patient cohort. In addition, we did not exclude patients with valve disease from this analysis. It is possible that the inclusion of patients with valve disease may be a confounding factor in the analysis; however valve disease was equally present in both groups and exclusion of patients with valve disease demonstrated no significant difference in survival in patients with preserved versus reduced LVF. Also it should be emphasized that there were significant differences in background diseases between the two groups that effect outcome. To overcome this we adjusted for such confounders, however there is a potential for bias despite the adjustments.

In conclusion, the prognosis of patients with clinical heart failure with or without preserved LVF is poor. An improved treatment protocol is needed in patients with HF with preserved LVF.

**Author Contributions**
Conceived and designed the experiments: IG. Analyzed the data: IG. Wrote the paper: IG DZ AK. Critical revision of the manuscript for important intellectual content: CL.

### Table 2. Predictors of death by Cox Regression analysis.

|                       | Preserved LVF (N = 111) | Reduced LVF (N = 198) | All (N = 309) |
|-----------------------|-------------------------|-----------------------|--------------|
| **HR (95% CI)**       | **P value**             | **HR (95% CI)**       | **P value**  |
| Age (years)           | 1.04 (1.02–1.07)        | 0.001                 | <0.001       |
| Gender (Male)         | 1.40 (0.80–2.42)        | 0.24                  | 1.91 (1.32–2.78) |
|                      | <0.001                  | 1.72 (1.28–2.31)      | <0.001       |
| Ischemic Heart Disease| 0.54 (0.33–0.89)        | 0.02                  | 0.99 (0.64–1.53) |
|                      | 0.97                    | 0.78 (0.57–1.06)      | 0.12         |
| Hypertension          | 0.82 (0.50–1.37)        | 0.45                  | 0.89 (0.64–1.23) |
|                      | 0.47                    | 0.86 (0.65–1.12)      | 0.26         |
| Diabetes Mellitus     | 0.89 (0.54–1.49)        | 0.66                  | 1.13 (0.79–1.62) |
|                      | 0.51                    | 1.09 (0.82–1.45)      | 0.55         |
| Atrial Fibrillation   | 1.04 (0.64–1.68)        | 0.88                  | 1.31 (0.91–1.88) |
|                      | 0.15                    | 1.22 (0.92–1.62)      | 0.17         |
| Admission due to HF   | 0.90 (0.55–1.47)        | 0.67                  | 1.00 (0.71–1.42) |
|                      | 0.99                    | 0.97 (0.73–1.28)      | 0.81         |
| Serum Na<135 mEq/L    | 1.25 (0.73–2.13)        | 0.41                  | 1.87 (1.29–2.71) |
|                      | 0.001                   | 1.69 (1.25–2.28)      | 0.001        |
| Serum Urea* (mmol/L)  | 1.74 (1.10–2.76)        | 0.02                  | 1.20 (0.91–1.57) |
|                      | 0.19                    | 1.34 (1.07–1.68)      | 0.01         |
| Hemoglobin (g/dl)     | 0.91 (0.79–1.04)        | 0.16                  | 0.92 (0.84–1.01) |
|                      | 0.08                    | 0.91 (0.84–0.98)      | 0.02         |
| NYHA FC Class III-IV  | 2.35 (1.30–4.24)        | 0.004                 | 1.98 (1.30–3.02) |
|                      | 0.001                   | 1.93 (1.39–2.68)      | <0.001       |
| Reduced LVF           | /                       | /                     | 1.16 (0.87–1.55) |
|                       | 0.31                    |                       |              |

*Log_{10}-transformed.

[12] doi:10.1371/journal.pone.0041022.t002
References

1. Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93: 1137–1146.
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, et al. (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355: 251–259.
3. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, et al. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355: 260–269.
4. Gotsman I, Zwas D, Planer D, Azaz-Livshits T, Admon D, et al. (2008) Clinical outcome of patients with heart failure and preserved left ventricular function. Am J Med 121: 997–1001.
5. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, et al. (2006) Systolic and diastolic heart failure in the community. Jama 296: 2209–2216.
6. Tribouilloy C, Rusinaru D, Mahjoub H, Soulere V, Levy F, et al. (2007) Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J.
7. Berry C, Hogg K, Norrie J, Stevenson K, Brett M, et al. (2005) Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 91: 907–913.
8. Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, et al. (2006) Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart 91: 489–494.
9. Lenzen MJ, Schole op Reimer WJ, Boersma E, Vantrimpont PJ, Foolash F, et al. (2004) Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 25: 1214–1220.
10. Miasoudi FA, Havranek EP, Smith G, Fish RH, Steiner JF, et al. (2003) Gender, age, and heart failure with preserved left ventricular systolic dysfunction. J Am Coll Cardiol 41: 217–223.
11. Gustafsson F, Torp-Pedersen C, Brenderup B, Seiback M, Burchardt H, et al. (2003) Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 24: 863–870.
12. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, et al. (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50: 768–777.
13. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurgemma GP, et al. (2001) Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 104: 779–782.
14. Kitzman DW, Little WC, Bruhaker PH, Anderson RT, Hundley WG, et al. (2002) Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. Jama 288: 2144–2150.
15. Tsutui H, Tsuchihashi M, Takeshita A (2001) Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88: 530–533.
16. Lam CS, Roger VL, Redheffer RJ, Bortlaug BA, Enders FT, et al. (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53: 1119–1126.
17. Zile MR, Baicu CF, Gaasch WH (2004) Diastolic heart failure abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350: 1953–1959.
18. Westermann D, Kanner M, Steenlidik P, Spillmann F, Riad A, et al. (2008) Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117: 2051–2060.
19. Solomon SD, Anavekar N, Kali H, McMurray JJ, Swedberg K, et al. (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112: 3738–3744.
20. (2011) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J.
21. Lewis BS, Shotan A, Gottlieb S, Behar S, Halon DA, et al. (2007) Late mortality and determinants in patients with heart failure and preserved systolic left ventricular function: the Israel Nationwide Heart Failure Survey. Isr Med Assoc J 9: 234–238.
22. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM (2003) Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 41: 1510–1518.
23. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47: 76–84.
24. Miyagishima K, Hiramitsu S, Kimura H, Mori K, Ueda T, et al. (2009) Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction. Circ J 73: 92–99.
25. Orea-Tejeda A, Colin-Ramirez E, Castillo-Martinez L, Asensio-Lafuente E, Corzo-Leon D, et al. (2007) Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Invest Clin 59: 103–107.